Real-world data on trastuzumab emtansine (TDM1) efficacy and safety: Results of a single-centre retrospective study of HER2-positive metastatic breast cancer patients
Abstract HER2-positive metastatic breast cancer (MBC) represents a challenging subtype of breast cancer, characterized by aggressive disease and poor clinical outcomes. Trastuzumab emtansine (TDM1), an antibody–drug conjugate combining trastuzumab and emtansine, has demonstrated efficacy in clinical...
Saved in:
| Main Authors: | Anuj Gupta, Bipinesh Sansar, Bal Krishna Mishra, Aqusa Khan, Arpita Singh, Arvind Upadhyay, Zachariah Chowdhury, Shashikant Patne, Mayank Tripathi, Shreya Shukla, Satyendra Narayan Singh, Lincoln Pujari, Prashanth Giridhar, Ankita Rungta Kapoor, Arvind Suresh, Somnath Dey, Kunal Ranjan Vinayak, Neha Singh, Amit Kumar, Ankita Pal, Akhil Kapoor |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-05-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-025-97923-2 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Trastuzumab emtansine in locally advanced or metastatic HER2 positive breast cancer; GENESIS-SEFH drug evaluation report
by: Patricia Miranda Romero, et al.
Published: (2015-02-01) -
Disitamab vedotin in preclinical models of HER2-positive breast and gastric cancers resistant to trastuzumab emtansine and trastuzumab deruxtecan
by: Negar Pourjamal, et al.
Published: (2025-03-01) -
The Clinical Utilisation and Duration of Treatment with HER2-Directed Therapies in HER2-Positive Recurrent or Metastatic Salivary Gland Cancers
by: Joseph Edward Haigh, et al.
Published: (2024-09-01) -
Ado-trastuzumab emtansine – The monoclonal drug conjugate in human epidermal growth factor receptor 2-positive breast cancer
by: Sandip Ganguly, et al.
Published: (2020-01-01) -
Impact of HER2 Status Assessed by Immunohistochemistry on Treatment Response in Patients with Metastatic Breast Cancer Receiving Trastuzumab Emtansine
by: Sila Oksuz, et al.
Published: (2025-04-01)